UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2008

or

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-14053

MILESTONE SCIENTIFIC INC.

(Exact name of registrant as specified in its charter)

Delaware		13-3545623
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

220 South Orange Avenue, Livingston, New Jersey 07039
(Address of principal executive offices)

(973) 535-2717

(Former name, former address and former fiscal year, if changed since last report)

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

þ Yes o No

     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o		Non-accelerated filer o		Smaller reporting company þ
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o Yes þ No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

o Yes o No

SEC1296 (02-08)		Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

As of May 15, 2008, the Issuer had a total of 12,202,186 shares of Common Stock, $.001 par value outstanding.

 

 

MILESTONE SCIENTIFIC INC

INDEX

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.
Condensed Balance Sheets March 31, 2008 (Unaudited) and December 31, 2007
Condensed Statements of Operations Three Months Ended March 31, 2008 and 2007 (Unaudited)
Condensed Statements of Changes in Stockholders’ Equity (Deficiency) Three Months Ended March 31, 2008 (Unaudited)
Condensed Statements of Cash Flow Three Months Ended March 31, 2008 and 2007 (Unaudited)
Notes to Condensed Financial Statement (Unaudited)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Submission of Matters to a Vote of Security Holders.
Item 5. Other Information.
Item 6. Exhibits.
SIGNATURES
CERTIFICATIONS
EX-31.1: CERTIFICATION
EX-31.2: CERTIFICATION
EX-32.1: CERTIFICATION
EX-32.2: CERTIFICATION

FORWARD-LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-Q, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act regarding events, conditions and financial trends that may affect Milestone’s future plans of operations, business strategy, results of operations and financial condition. Milestone wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone’s reports and registration statements filed with the Securities and Exchange Commission (the “Commission”). Milestone disclaims any intent or obligation to update such forward-looking statements.

ITEM 1. FINANCIAL STATEMENTS

MILESTONE SCIENTIFIC INC.

CONDENSED BALANCE SHEETS

		March 31, 2008				December 31, 2007
		(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents		$	237,716			$	745,003
Accounts receivable , net of allowance for doubtful accounts of $5,000 in 2008 and 2007			344,348				346,347
Royalty receivable			14,163				15,358
Inventories			1,338,572				1,636,744
Advances to contract manufacturer			1,193,551				1,192,584
Prepaid expenses			204,717				169,727
Total current assets			3,333,067				4,105,763
Investment in distributor, at cost			76,319				76,319
Equipment, net of accumulated depreciation of $302,885 as of March 31, 2008 and $284,145 as of December 31, 2007			204,999				220,808
Patents, net of accumulated amortization of $90,441 of March 31, 2008 and $79,498 as of December 31, 2007			645,193				559,378
Other assets			24,551				27,297
Total assets		$	4,284,129			$	4,989,565
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	1,466,302			$	1,855,835
Accrued expenses			285,300				201,103
Deferred compensation payable to officers			30,376				15,833
Total current liabilities			1,781,978				2,072,771
Long-term Liabilities:
Accounts payable-long term			—			$	443,847
Line of credit-net of discount of $59,242 and $65,371, respectively			940,758				934,629
Total long-term liabilities			940,758				1,378,476
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $.001; authorized 50,000,000 shares; 12,119,143 shares issued 504,639 shares to be issued, and 12,085,810 shares outstanding in 2008; 11,787,572 shares issued, 421,306 shares to be issued, and 11,754,239 shares outstanding in 2007			12,625				12,210
Additional paid-in capital			59,122,084				58,483,539
Accumulated deficit			(56,661,800	)			(56,045,915	)
Treasury stock, at cost, 33,333 shares			(911,516	)			(911,516	)
Total stockholders’ equity			1,561,393				1,538,318
Total liabilities and stockholders’ equity		$	4,284,129			$	4,989,565

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

		Three Months Ended March 31,
		2008				2007
Product sales, net		$	1,387,990			$	2,262,027
Royalty income			14,163				47,936
Total revenue			1,402,153				2,309,963
Cost of products sold			463,924				831,210
Royalty expense			—				5,752
Total cost of revenue			463,924				836,962
Gross profit			938,229				1,473,001
Selling, general and administrative expenses			1,471,978				1,836,888
Research and development expenses			48,319				178,566
Total operating expenses			1,520,297				2,015,454
Loss from operations			(582,068	)			(542,453	)
Interest expense			(30,924	)			—
Interest-Amortization of debt issuance			(6,129	)			—
Interest income			3,236				7,336
Net loss applicable to common stockholders		$	(615,885	)		$	(535,117	)
Loss per share applicable to common stockholders - basic and diluted		$	(0.05	)		$	(0.05	)
Weighted average shares outstanding and to be issued - basic and diluted			12,262,256				11,958,098

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

THREE MONTHS ENDED MARCH 31, 2008

(Unaudited)

										Additional
		Common Stock								Paid-in				Accumulated				Treasury
		Shares				Amount				Capital				Deficit				Stock				Total
Balance, January 1, 2008			12,208,878			$	12,210			$	58,483,539			$	(56,045,915	)		$	(911,516	)		$	1,538,318
Options issued to employees and consultants			—				—				34,281												34,281
Common stock issued for payment of services			156,448				157				262,591												262,748
Common stock issued for payment of consulting services			165,780				166				225,933												226,099
Common stock issued for payment of employee compensation			9,314				9				15,823												15,832
Common stock to be issued for settlement of deferred compensation			83,333				83				99,917												100,000
Net loss															(615,885	)							(615,885	)
Balance, March 31, 2008			12,623,753			$	12,625			$	59,122,084			$	(56,661,800	)		$	(911,516	)		$	1,561,393

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

		THREE MONTHS ENDED MARCH 31,
		2008				2007
Cash flows from operating activities:
Net loss		$	(615,885	)		$	(535,117	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense			18,740				24,853
Amortization of patents			10,943				5,712
Amortization of debt discount			6,129				—
Common stock and options issued for compensation, consulting and vendor services			638,960				283,501
Bad debt expense			—				5,688
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable			1,999				(1,073,202	)
Decrease in royalty receivable			1,195				12,171
Decrease in inventories			298,172				98,926
Increase to advances to contract manufacturer			(967	)			(19,064	)
(Increase) to prepaid expenses and other current assets			(34,990	)			(25,485	)
Decrease in other assets			2,746				947
(Decrease) increase in accounts payable			(833,380	)			265,914
Increase in accrued expenses			84,197				217,059
Increase in deferred compensation			14,543				44,497
Net cash used in operating activities			(407,598	)			(693,600	)
Cash flows from investing activities:
Purchases of property and equipment			(2,931	)			(15,314	)
Payment for patents rights			(96,758	)			—
Net cash used in investing activities			(99,689	)			(15,314	)
NET DECREASE IN CASH AND CASH EQUIVALENTS			(507,287	)			(708,914	)
Cash and cash equivalents at beginning of period			745,003				1,160,116
Cash and cash equivalents at end of period		$	237,716			$	451,202
Supplemental disclosure of cash flow information:
Interest expense paid in cash			—				—
Income taxes paid		$	3,140				—

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.

NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

NOTE A — ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION

Milestone Scientific Inc. (“Milestone”) was incorporated in the State of Delaware in August 1989.

The unaudited financial statements of Milestone Scientific Inc. (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2007 included in Milestone’s Annual Report on Form 10-KSB. The accounting policies used in preparing these unaudited financial statements are the same as those described in the December 31, 2007 financial statements.

In the opinion of Milestone, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone’s financial position as of March 31, 2008 and December 31, 2007 and the results of its operations for the three months ended March 31, 2008 and 2007.

The results reported for the three months ended March 31, 2008 are not necessarily indicative of the results of operations which may be expected for a full year.

The Company has incurred operating losses and negative cash flows from operating activities since its inception, including a net loss of $615,885 and $535,117 for the three months ended March 31, 2008 and 2007, respectively. At March 31, 2008, the Company had cash and cash equivalents and working capital of $237,716 and $1,551,089, respectively. Additionally, as discussed in Note B-10, on June 28, 2007, the Company secured a revolving line of credit in the aggregate amount of $1,000,000 from a stockholder which line was fully borrowed at December 31, 2007. The Line of Credit subsequent to March 31, 2008 was increased by $300,000 to $1,300,000. All terms and conditions remain unchanged. The Company is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses; however, the Company does not now have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months. The Company anticipates the need for a higher level of marketing and sales efforts that at present it cannot fund. If the Company is unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that traditional capital can be raised on terms and conditions satisfactory to the Company, if at all. If additional capital is required and it cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company’s operating results.

The Company’s recurring losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On November 6, 2007 Milestone entered into a Collaboration Agreement (the “Agreement”) with a global diversified healthcare company (the “Collaborator”) to conduct a feasibility study to evaluate the potential application of Milestone’s proprietary CompuFlo Injection System for injecting medicaments. The name of the company is not provided pursuant to the confidentiality provisions in the Agreement. Under the terms of the Agreement, Milestone will provide, at no cost to the Collaborator, a mutually agreed quantity of CompuFlo Injection Systems and training on proper operation of the systems for use in the feasibility study. All other costs and expenses associated with the feasibility study will be the

responsibility of the Collaborator. The Collaborator may terminate the Agreement at any time upon at least ten (10) days prior written notice to Milestone, provided that the Collaborator shall be responsible for any reasonable, non-cancelable costs and expenses incurred by Milestone or its approved subcontractors prior to the date of termination. There can be no assurance that the feasibility study will be successfully concluded or, if successfully concluded, that it will lead to any further agreements with the Collaborator for their use of Milestone’s technology or products.

NOTE B — SUMMARY OF ACCOUNTING POLICIES

1. Cash and Cash Equivalents

Milestone considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.

2. Inventories

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market.

3. Patents

Patents are recorded at actual cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. Although certain patents have not yet been approved, the costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. If the applicable patent application is ultimately rejected, the remaining unamortized balance will be expensed in the period in which the Company receives a notice of such rejection. Patent applications filed and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may be different from patent protection under United States laws and may not be favorable to the Company. The Company also attempts to protect our proprietary information through the use of confidentiality limiting access to our facilities. There can be no assurance that our program of patents, confidentiality agreements and restricted access to our facilities will be sufficient to protect our proprietary technology.

4. Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to our domestic distributor on the date of arrival of the goods at the customer’s location as shipments are FOB destination. Shipments to our international distributors are FOB our warehouse and revenue is therefore recognized on shipment. In both cases, the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post sale installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Our only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

Royalty income is recognized as earned based on reports received from the licensee and related royalty expense is accrued during the same period.

5. Basic and diluted net loss per common share

Milestone presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards No. 128, “Earnings per Share” (SFAS 128). Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of preferred stock were issued during the period.

Since Milestone had net losses for the three months ended March 31, 2008 and 2007, the assumed effects of the exercise of outstanding stock options and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled 3,343,746 at March 31, 2008 and 3,644,920 at March 31, 2007.

6. Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

7 Stock Option Plans

Effective January 1, 2006 Milestone adopted SFAS No. 123R, “Share-Based Payment, an Amendment of FASB Statement No. 123” (SFAS No. 123R), under the modified-prospective transition method whereby prior periods will not be restated for comparability. SFAS No. 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations over the service period, as an operating expense, based on the grant-date fair values. Pro-forma disclosure is no longer an alternative. As a result of adopting SFAS No. 123R, Milestone recognizes as compensation expense in its financial statements the unvested portion of existing options granted prior to the effective date and the cost of stock options granted to employees after the effective date based on the fair value of the stock options at grant date. Prior to the adoption of SFAS No. 123R, Milestone accounted for its stock option plans using the intrinsic value method of accounting prescribed by APB Opinion No. 25.

A summary of option activity for employees under the plans as of March 31, 2008, and changes during the three months ended is presented below:

										Weighted
						Weighted				Average				Aggregate
		Number				Averaged				Remaining				Intrinsic
		of				Exercise				Contractual				Options
		Options				Price				Life (Years)				Value
Outstanding, January 1, 2008			391,334				1.86				2.54			$	108,800
Granted			33,333				1.15				4.86				—
Exercised			—				—				—				—
Forfeited or expired			(36,334	)			1.20				—				—
Outstanding, March 31, 2008			388,333				1.86				3.01				—
Exercisable, March 31, 2008			293,111				2.00				2.61				—

The weighted average grant date fair value of options granted to employees during the three months ended March 31, 2008 was $1.15. The fair value of the options was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: expected life three years, volatility of 285% and a risk free interest rate of 3.77%.

Milestone recognizes compensation expense on a straight line basis over the requisite service period. During the three months ended March 31, 2008, Milestone recognized $20,729 of total compensation cost related to options that vested during the period. As of March 31, 2008, there was $47,897 of total unrecognized compensation cost related to non-vested options which Milestone expects to recognize over a weighted average period of two and three quarter years.

As of March 31, 2008, the Fair Market Value of the Company’s stock was less than the exercise price of the options, therefore there is no aggregate intrinsic value calculated.

A summary of option activity for non-employees under the plans as of March 31, 2008 and changes during the three months ended is presented below:

										Weighted
						Weighted				Average				Aggregate
		Number				Averaged				Remaining				Intrinsic
		of				Exercise				Contractual				Options
		Options				Price				Life (Years)				Value
Outstanding, January 1, 2008			639,133				3.15				2.56			$	20,667
Granted			—				—				—				—
Exercised			—				—				—				—
Forfeited or expired			(11,666	)			—				—				—
Outstanding, March 31, 2008			627,467				3.14				2.36				—
Exercisable, March 31, 2008			502,467				3.48				1.99				—

During the three months ended March 31, 2008, Milestone recognized $13,552 of expenses related to non-employee options that vested during the year. The total unrecognized compensation cost related to non-vested options was $100,137 as of March 31, 2008.

As of March 31, 2008, the Fair Market Value of the Company’s stock was less than the exercised price of the options, therefore, there was no aggregate intrinsic value calculated.

In accordance with the provisions of SFAS No.123R, all other issuances of common stock, stock options or other equity instruments to non-employees as consideration for goods or services received by Milestone are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options or similar equity instruments issued is estimated based on the Black-Scholes option-pricing model, which meets the criteria set forth in SFAS No. 123, and the assumption that all of the options or other equity instruments will ultimately vest. Such fair value is measured as of an appropriate date pursuant to the guidance in the consensus of the Emerging Issues Task Force (“EITF”) for EITF Issue No. 96-18 (generally, the earlier of the date the other party becomes committed to provide goods or services or the date performance by the other party is complete) and capitalized or expensed as if Milestone had paid cash for the goods or services.

Expected volatilities are based on historical volatility of Milestone’s common stock over a period commensurate with expected term. Milestone uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of the options granted was estimated using the simplified method as the average of the contractual term and vesting term of the option.

8. Concentration of Credit Risk

Milestone’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and trade accounts receivable, and advances to contract manufacturer. Milestone places its cash and cash equivalents with large financial institutions. At times, such investments may be in excess of the Federal Deposit Insurance Corporation insurance limit. Milestone has not experienced any losses in such accounts and believes it is not exposed to any significant credit risks. Financial instruments which potentially subject Milestone to credit risk consist principally of trade accounts receivable, as Milestone does not require collateral or other security to support customer receivables, and advances to contract manufacturer. Milestone entered into a purchase agreement with a vendor to supply Milestone with 5,000 units of CompuDent. As part of this agreement, Milestone has advanced approximately $1.2 million to the vendor for purchase of materials at March 31, 2008. The advance will be credited to Milestone as the goods are delivered. Milestone does not believe that significant credit risk exists with respect to this advance to the contract manufacturer at March 31, 2008.

Milestone closely monitors the extension of credit to its customers while maintaining allowances, if necessary, for potential credit losses. On a periodic basis, Milestone evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Management does not believe that significant credit risk exists with respect to accounts receivable at March 31, 2008.

9. Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” This new standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This statement does not require any new fair value measurements but provides guidance in determining fair value measurements presently used in the preparation of financial statements. This new standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. This Standard was adopted as of January 1, 2008 and did not have a significant impact on Milestone’s results of operations or financial position.

In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No.159, “The Fair Value Option for Financial Assets and Financial Liabilities –Including an amendment of FASB Statement No. 115”. SFAS No.159 permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No.159 is effective as of the first fiscal year that begins after November 15, 2007. This Standard was adopted as of January 1, 2008, and did not have any impact on Milestone’s results of operations or financial position.

In December 2007, the Financial Accounting Standards Board (FASB) issued SFAS No.141 (revised), “Summary No. 141 (revised 2007)”. SFAS No.141 (revised) provides for improving the relevance, representational faithfulness, and comparability of the information that an entity provides in its financial reports about a business combination and its effects. SFAS No.141 (revised) applies prospectively to business combinations for which the acquisition date is on or after December 15, 2008. Milestone is considering the impact of this Statement on its financial statements.

In December 2007, the Financial Accounting Standards Board (FASB) issued SFAS No.160, “Non-controlling Interest in Consolidated Financial Statements- and amendment of ARB No. 51”. SFAS No.160 establishes accounting and reporting standards for non-controlling interests, sometimes called minority interests, the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. SFAS No.160 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2008. Milestone will consider the impact of this Statement in 2009.

10. Line of credit

On June 28, 2007 the Company secured a $1 million line of credit from a stockholder. Borrowings bear interest at 6% per annum, with one year’s interest at 1% payable in advance on each draw. Borrowings and subsequent repayments may be made from time to time, in increments of $100,000, until the expiration date for borrowing under the line of credit on December 31, 2008. All borrowings and interest thereon must be repaid by June 30, 2010, and after the expiration date of the line, may be repaid by Milestone in cash or, at its option, in shares of common stock valued at the lower of $2.00 per share or 80% of the average closing price of its shares during the 20 days ending with December 31, 2008. After December 31, 2008, and before June 30, 2010 the lender may convert all or any part of the then outstanding balance and interest thereon into shares of Common Stock at $4.00 per share. Three year warrants exercisable at $5.00 per share, in an amount determined by dividing 50% of the amount borrowed by $5.00 will be issued on each drawdown. There is no facility fee on the line. The warrants have been valued as of each draw down using the Black-Scholes model and are reflected as a discount against the debt incurred under this line of credit. At March 31, 2008 the remaining balance of Debt Discount was $59,242. The full amount of the line of credit, $1 million, has been drawn at December 31, 2007. Interest expense on this Line of Credit for the three months ended March 31, 2008 is $30,923. Additionally, the charge for amortization of Debt Discount related to this Line of Credit is $6,129.

Subsequent to March 31, 2008, the above line of credit was increased by $300,000 to $1,300,000. All term and conditions remain unchanged.

11. Significant customers

During the three months ended March 31, 2008 and 2007, Milestone had two customers (distributors) who in the aggregate accounted for approximately 93% and 59% respectively, of its net product sales for the three months ended March 31, 2008 and 2007. Milestone had sales to one customer (a worldwide distributor of Milestone’s products based in South Africa) of approximately $255,311. This represented 18% of the total net product sales for the three months ended March 31, 2008. Accounts receivable from these two customers amounted to approximately $336,905 and $1,290,714

representing 98% and 91% of gross accounts receivable for the three months ended March 31, 2008 and 2007, respectively.

Milestone’s sales by product and by geographical region are as follows:

		Three Months Ended March 31,
		2008				2007
CompuDent		$	134,189			$	338,307
STA Units			85,016				632,309
Handpieces			1,141,750				1,203,932
STA Handpieces			34,641				20,545
Other			(7,606	)			66,934
		$	1,387,990			$	2,262,027
United States		$	897,715			$	1,904,344
Canada			160,322				148,978
Other Foreign			329,953				208,705
		$	1,387,990			$	2,262,027

In January 2007, Milestone finalized an Exclusive Distribution and Supply Agreement with Henry Schein, Inc. Henry Schein, Inc. will serve as the exclusive distributor of STA and CompuDent systems (and ancillary products) in both North America and Canada, for a one year period. The exclusive period has expired and the Company is considering alternative marketing and distribution strategies that we believe will help us to accelerate and drive sales momentum.

The Company has informal arrangements with the manufacturer of our STA, CompuDent and CompuMed units, one of the principal manufacturers of our handpieces and for those units pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. The Company has a manufacturing agreement with one of the principal manufacturers of our handpieces pursuant to which they manufacture products under specific purchase orders but without minimum purchase commitments. The Company has established an alternate source of supply for our handpieces in China and other alternate sources of supply exist.

12. Commitments and Other

Contract Manufacturing Arrangement

Milestone has informal arrangements for the manufacture of its products. CompuDent and CompuMed units are manufactured for Milestone by Tricor Systems, Inc. pursuant to specific purchase orders. The Wand disposable handpiece is manufactured for Milestone in Mexico pursuant to scheduled production requirements. The Wand Handpiece with Needle is supplied to Milestone by the licensee of Milestone’s proprietary consumer dental whitening product, which arranges for its manufacture by manufacturers in China.

The termination of the manufacturing relationship with any of the above manufacturers could have a material adverse effect on Milestone’s ability to produce and sell its products. Although alternate sources of supply exist and new manufacturing relationships could be established, Milestone would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, whether or not as a result of termination of such a relationship, would adversely affect Milestone.

Other Commitments

Milestone acquired the technology underlying our CoolBlue Professional Whitening and Ionic White Consumer Whitening Products. Under the terms of a licensing agreement with a third party manufacturer, we will receive licensing

fees resulting from the sales of the consumer whitening product. Through December 31, 2006, Milestone paid royalties in connection with the tooth whitening products to a purported holder of patent rights therein. Late in 2006 Milestone received a copy of a patent office filing which appeared to show that the purported owner had relinquished rights to the patent on which royalties had been paid. It is possible that, never-the-less, the purported owner may claim continuing rights to receive royalties or that others may claim that payments are owed in connection with Milestone’s prior sales. Milestone has continued to accrue royalties due but has ceased making cash payments. In 2007, Milestone stopped the sale of this product in the United States and has written off the cost of patents relating to this product.

On August 24, 2007 Milestone commenced a Declaratory Judgment Action against Milton Hodosh, DMD in the United States District Court for the District of New Jersey seeking a determination by that Court that neither its Single Tooth Anesthesia (STA) System nor its CompuDent system infringed claims set forth in United States Patent No. 6159161 by Dr. Hodosh on July 8, 1998 and issued by the United States Patent Office on December 12, 2000. Milestone’s basic patents covering these systems were issued by the United States Patent Office in January 1993. Subsequent to the commencement of Milestone’s action for Declaratory Judgment, Dr. Hodosh commenced a patent infringement suit in the United States District Court for the Southern District of New York. Milestone has received opinions from patent counsel, not involved in the litigation, to the effect that neither the STA System nor the CompuDent systems infringe any of the claims of Dr. Hodosh’s patents. Milestone believes that it has meritorious defenses to Dr. Hodosh’s action and it intends to vigorously defend this law suit. The case is currently in the discovery phase.

Subsequent Events

Subsequent to March 31, 2008, the line of credit from a stockholder was increased by $300,000 to $1,300,000. All terms and conditions remain unchanged.

ITEM 2. Management’s Discussion and Analysis and Plan of Operation.

          The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements. See “Risk Factors” on Part II. ITEM 1A of this Form 10-Q.

OVERVIEW

During the first quarter of 2008, we continued to focus our efforts on executing a long-term growth strategy that is specifically designed to:

	•		optimize our tactical approach to product sales and marketing in order to increase penetration of the global dental and medical markets with our proprietary, patented Computer-Controlled Local Anesthesia Delivery (CCLAD) solutions; and
	•		identify and pursue strategic collaborations with third parties to jointly develop new products utilizing our CompuFlo pressure force technology for novel, new dental and medical applications.

          In order to achieve the goals and objectives of the Company, it is essential that we have the best people possible. In September of 2007 Robert (Bob) Presutti joined Milestone as the Vice President of Sales and Marketing. Bob has assembled a sales and marketing team that is having a positive impact on optimizing our sales and marketing strategies, and is developing innovative tactics and action plans to achieve those strategies. In January of 2008, Joseph D’Agostino joined Milestone as the Acting Chief Financial Officer. Joseph has skills, talents and experience that is necessary to help Milestone grow and develop in all areas of operations. He, too, has had a very positive impact on our business.

          In February 2007, the STA System was formally unveiled to market at the 142nd Chicago Dental Society Midwinter Meeting, one of the largest dental trade events held each year in the U.S. Following considerable media attention in the national, business and trade press, STA product shipments commenced in late March 2007.

          Unfortunately, the anticipated sales ramp-up for the instrument did not meet our initial expectations. Consequently, Milestone conducted a comprehensive market research study to closely evaluate product perception and pricing, and to reassess our product messaging and tactical approach to the dental community. The study involved surveying early STA System adopters, prospective customers and industry thought leaders.

          What we learned from our market research is that we have not properly communicated to the dental community that the STA System can be used for ALL injections, not only the “Single Tooth Anesthesia,” or periodontal intraligamentary (PDL), injection. As a result, the instrument’s value proposition was not being optimized. Our research also confirmed that when giving injections using hypodermic syringes to patients, many, if not most, dentists experience a similar level of fear, stress and discomfort as the patient undergoing the actual treatment. However, according to Marty Jablow, DMD, a dental practitioner in Woodbridge, New Jersey, “The STA System allows me to begin every injection technique with significantly less stress for me and the patient.”

          In late November 2007, we implemented a refined messaging platform that is helping us position the products and its utility by dental practitioners. Further, with the addition of a new Director of Marketing, Scott Mahnken, who joined the marketing team in February of this year, Milestone has been implementing specific action plans to get its clarified message out to the market. Additionally, we have made pricing adjustments to the STA System that align with the perceived market value. At the Chicago Dental Society’s 143^rd Midwinter Meeting, held in late February 2008, traffic through both Milestone’s and Henry Schein’s exhibit areas remained highly fluid and resulted in a significant number of STA Systems being sold to attendees over the three day event, contributing to record STA System purchases by dentists during the month of February 2008.

          To perpetuate our progress and instigate further discussion and analysis of our marketing strategies on a going forward basis, we hosted the First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit in New Orleans in early February 2008. The Summit welcomed a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the science, knowledge and clinical utility of CCLAD in dentistry. This highly productive and interactive forum yielded a number of compelling suggestions and recommendations from the panel on the clinical value and practical utility of the STA System to the dental community.

          The management teams at Milestone and our primary distributor in the U.S. and Canada, recognize that we have not had the appropriate sales focus, or the market attention to drive a successful new domestic product launch. Nonetheless, the STA System has performed extremely well in the field. Based on our new customer surveying, those dentists who have acquired and now use the instrument, are both impressed and satisfied with its performance and user benefits. Consequently, we are engaged in alternative marketing and distribution strategies that we believe will help us accelerate and drive the sales momentum in 2008

          The STA System continues to be recognized by leading industry publications as one of the best dental innovations. In April 2008, the Medical Device & Diagnostic Industry (MD&DI) magazine distinguished the STA System as a winner of the 2008 Medical Design Excellence Award (MDEA) in the “dental instruments, equipment and supplies” product category. Of the 33 products to receive an MDEA this year, Milestone’s STA System was one of only two winning products that serve dental practitioners. In July 2007, noted industry publication Dentistry Today featured the STA System as one of the Top 100 Products in 2007.

          In June of 2007, Milestone was granted a CE Mark approval of the STA System, which in turn triggered our preparation for introducing the instrument to dental professionals in European Union countries and other countries around the world that recognize the CE Mark approval process. In collaboration with our international distribution partners, we anticipate formally launching the sales and marketing of the STA System in South Africa in May 2008 and in selected European countries beginning in the summer of 2008.

          Following clearance of the 510(k) Pre-market Notification for the sale and marketing of our patented CompuFlo technology, which we received from the U.S. Food and Drug Administration in July 2006, Milestone commissioned an in-depth, independent market study. Together, they provide clients in the life science industries with single-source access to a full range of marketing services, from analysis through complete strategic implementation. Tasked with identifying practical industry applications using our CompuFlo technology platform. The study concluded that applications for CompuFlo exceeded 700, including both medical and extra-medical uses.

          In March 2007, Milestone signed a collaborative agreement with an Atlanta-based company developing and commercializing advanced medical instrument technology for the minimally-invasive treatment of cartilage damage and osteoarthritis. At that time, the companies agreed to collaborate, at our collaborator’s expense, on the development of a specialized injection system using Milestone’s CompuFlo technology to painlessly inject the collaborator’s proprietary products in the intra-articular joint space. Animal studies performed under the Collaboration Agreement demonstrated to our collaborator’s satisfaction that the prototype could meet its predetermined performance benchmarks, leading us to commence negotiations for the development of a commercial product and for a Distribution Agreement between our companies. However, we did not prove successful in reaching an agreement and consequently, in September 2007, it was decided to terminate negotiations.

          In November 2007, we entered into a collaborative agreement with a globally diversified healthcare company to conduct a feasibility study evaluating the potential application of our CompuFlo technology for injecting certain medicaments produced by this company. We have completed the initial study and are now hoping to leverage its findings to progress strategic discussions and explore product development opportunities with the company.

          Our focus in 2008 has and will continue to be largely centered on increasing sales of the STA System, both domestically and internationally, as well as supporting sales of our legacy CCLAD system, CompuDent and driving recurring orders of the disposable hand pieces used in conjunction with both instruments. The challenge going forward will be leveraging creative and tactical advertising and proactive marketing strategies to spread the ‘right’ message about the STA System to each and every dentist.

          As we continue to advance through 2008, Milestone will persist in identifying and pursuing opportunities for only those applications for CompuFlo that have been deemed by management as the most promising and viable and have the greatest potential for near term strategic alliances and revenue contribution, with specific emphasis on new medical applications for the home market for self administrated drugs, injections for osteoarthritis and epidurals.

          The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

		Three Months Ended March 31,
		2008								2007
DOMESTIC
CompuDent		$	65,570				7.3	%		$	287,227				15.1	%
STA units			15,574				1.7	%			632,309				0.0	%
Handpieces			793,818				88.4	%			911,971				82.2	%
STA handpieces			31,091				3.5	%			20,545				0.0	%
Other			(8,338	)			-0.9	%			52,292				2.7	%
Total Domestic		$	897,715				100.0	%		$	1,904,344				100.0	%
INTERNATIONAL
CompuDent		$	68,619				14.0	%		$	51,080				14.3	%
STA units			69,442				14.2	%			—				0.0	%
Handpieces			347,932				71.0	%			291,961				81.6	%
STA handpieces			3,550				0.7	%			0				0.0	%
Other			732				0.1	%			14,642				4.1	%
Total International		$	490,275				100.0	%		$	357,683				100.0	%
DOMESTIC/INTERNATIONAL ANALYSIS
Domestic		$	897,715				64.7	%		$	1,904,344				84.2	%
International			490,275				35.3	%			357,683				15.8	%
Total Product Sales		$	1,387,990				100.0	%		$	2,262,027				100.0	%

          The Company earned gross profits of 67% and 64% in for the three months ended March 31, 2008 and 2007, respectively. However, our revenues and related gross profits have not been sufficient to support our overhead, new product introduction and research and development expenses. Although the Company anticipates expending funds for research and development in 2008, these amounts will vary based on the operating results for each quarter. The Company has incurred operating losses and negative cash flows from operating activities since its inception. The Company is actively pursuing the generation of positive cash flows from operating activities through increase in revenue, assessment of current contracts and current negotiations and reduction in operating expenses; however the Company does not have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months.

     Technology Rights

          The technology underlying our SafetyWand and CompuFlo technology and an improvement to the controls for CompuDent were developed by our Director of Clinical Affairs and assigned to us. We purchased this technology pursuant to an agreement dated January 1, 2005, for 43,424 shares of restricted common stock and $145,000 in cash, paid on April 1, 2005. In addition, our Director of Clinical Affairs will receive additional deferred contingent payments of 2.5% of our total sales of products using some of these technologies, and 5% of our total sales of products using some of our other technologies. If products produced by third parties use any of these technologies, under a license from Milestone, then he will also receive the corresponding percentage of the consideration received by us for such sale or license.

     Summary of Significant Accounting Policies, Judgments and Estimates

          Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles, generally accepted in the U.S.. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis,

we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions. See NOTE B. ITEM 1. FINANCIAL STATEMENTS

Accounts Receivable

          The realization of Accounts Receivable will have a significant impact on the Company. Consequently, Milestone estimates losses resulting from the inability of its customers to make payments for amounts billed. The collectability of outstanding amounts is continually assessed.

Inventories

          Inventory costing, obsolescence and physical control is significantly important to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

Impairment of Long-Lived Assets

          The long lived assets of the Company, principally patents and trademarks are the base features of the business. We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

Revenue Recognition

          Revenue from product sales is recognized net of discounts and allowances to our domestic distributor on the date of arrival of the goods at the customer’s location as shipments are FOB destination. Shipments to our international distributor are FOB our warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Our only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

          Royalty income is recognized as earned based on reports received from the licensee and related royalty expense is accrued during the same period.

Use of Estimates

          The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

Results of Operations

          The consolidated results of operations for the three months ended March 31, 2008 compared to the same three month period in 2007 reflect our focus and development into the STA System delivery system, as well continuing efforts on the CompuFlo technology.

          The following table sets forth for the periods presented statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

		Three Months Ended March 31
		2008								2007
Products sales, net		$	1,387,990				99	%		$	2,262,027				98	%
Royalty income			14,163				1	%			47,936				2	%
Total revenue			1,402,153				100	%		$	2,309,963				100	%
Cost of products sold			463,924				33	%			831,210				36	%
Royalty expense			—				—				5,752				0	%
Total cost of revenue			463,924				33	%			836,962				36	%
Gross Profit			938,229				67	%			1,473,001				64	%
Selling, general and administrative expenses			1,471,978				105	%			1,836,888				79	%
Research and development expenses			48,319				3	%			178,566				8	%
Total operating expenses			1,520,297				108	%			2,015,454				87	%
Loss from operations			(582,068	)			-42	%			(542,453	)			-23	%
Other income — interest & expense			(33,817	)			-2	%			7,336				0	%
Net loss		$	(615,885	)			-44	%		$	(535,117	)			-23	%

Three months ended March 31, 2008 compared to three months ended March 31, 2007

          Total revenues for the three months ended March 31, 2008 and 2007 were $1,402,153 (product sales of $1,387,990 and royalty income of $14,163) and $2,309,963 (product sales of $2,262,027 and royalty income of $47,936) respectively. The total decrease in product sales of $874,037, 38.6% in 2008 over 2007 is a direct result of the STA product launch in the first quarter of 2007 that did not continue into 2008 first quarter. The decrease in unit sales of domestic units $848,392, 92.2% in 2008 over 2007, was due to a lack of sales by our exclusive distributor. In the domestic market, handpiece sales also were lower by $107,607 or 11.5%, due to a lack of sales performance by our exclusive distributor. On the international scene, unit sales increased in the first quarter of 2008 over 2007 by $86,981 or 170.3% principally due to the introduction of the STA product. Internationally, handpieces also increased. The increase in handpieces internationally was $59,521, 20.3% due to an increase in CompuDent handpieces. Other revenue decreased by $74,540 principally due to a decrease in Cool Blue tooth whitening product base. The Company decided to exit the Cool Blue business beginning in 2007.

          Royalty income resulted from granting United Systems Inc. a license to manufacture, market, and sublicense the Ionic White™ to the consumer market. Royalty income for the three months ended March 31, 2008 and 2007, respectively, was $14,163 and $47,936. The decrease of $33,773 or 70.3% reflecting increased retail competition in this increasingly highly competitive market.

          Cost of products sold for the three months ended March 31, 2008 and 2007 were $463,924 and $831,210, respectively. The $367,286 or 44.2% decrease is primarily attributable a reduction in sales volume.

          For the three months ended March 31, 2008, Milestone generated a gross profit of $938,229 or 67% as compared to a gross profit of $1,473,001 or 64% for the three months ended March 31, 2007. The increase in gross profit percentage was due to the launching of the STA System with an exclusive distributor operational base. The total reduction in gross profit of $534,772 is due to a reduction in sales volume.

          Selling, general and administrative expenses for the three months ended March 31, 2008 and 2007 were $1,471,978 and $1,836,888 respectively. The $364,910 or 20% net decrease spanned several key areas of the Company. Salaries increased by $124,474 for the three months ended March 31, 2008 over 2007. This increase for the three months ended March 31, 2008 over 2007 was primarily attributable to the addition of a Chief Executive Officer and a marketing executive along with the recognition of deferred compensation expense for an officer of the Company. Conversely, the STA launch in 2007 did not reoccur in the first quarter of 2008. As a result, expenses in this category in the first quarter of

2008 decreased by $174,624 principally in marketing, travel, printing and sample expenses. The new exclusive distributor operating model (initiated in 2007) resulted in a savings to the Company of $81,348 in 2008 over 2007. Royalty expense for the sale of Milestone products decreased by $5,752 as a result of fewer units sold during first quarter of 2008 compared to 2007. Professional fees increased by $45,151 in 2008 over 2007, including costs incurred with a third party for the implementation of Sarbanes Oxley compliance documentation and testing. Consultant costs increased by approximately $151,479 based on application of SFAS 123 R, stock based Compensation.

          Research and development expenses for the three months ended March 31, 2008 and 2007 were $48,319 and $178,566, respectively. The decrease of $130,247 was attributable to a reduction in such cost in 2008 after the launch of STA product in the first quarter of 2007.

          The loss from operations for the three months ended March 31, 2008 and 2007 was $582,068 and $542,453, respectively. The $39,615 or 7.3% increase in loss from operations is explained above.

          Interest income of $3,236 was earned for the three months ended March 31, 2008 compared with $7,336 for the same period in 2007. Interest income declined due to lower cash balances and lower interest rates.

          Interest expense was $37,052 (interest $30,923 and amortization of debt issuance of $6,129), related to the line of credit established in June 2007 (second quarter).

          For the reasons explained above, net loss for the three months ended March 31, 2008 was $615,885 as compared to a net loss of $535,117 for the three months ended March 31, 2007. The $80,764 or 15% increase in net loss is primarily a result of the decreased sales and gross margin dollars, partially benefited by a reduction in selling, general and administrative expenses.

Liquidity and Capital Resources

          As of March 31, 2008, we had cash and cash equivalents of $237,716 and working capital of $1,551,088 Milestone incurred net losses of $615,885 and $535,117 and negative cash flows from operating activities of $407,598 and $693,600 for the three months ended March 31, 2008 and 2007, respectively.

          For the three months ended March 31, 2008, our net cash used in operating activities was $507,287. This was attributable primarily to a net loss of $615,885 adjusted for noncash items of $674,771 and changes in operating assets and liabilities of $466,485, principally common stock and options issued for compensation, consulting and vendor services.

          For the three months ended March 31, 2008, Milestone used $99,689 in investing activities. This was primarily attributable to $96,758 of legal fees related to new patent application. Capital expenditures of $2,931 were primarily for the purchase of molds and tooling for new products.

          As of March 31, 2008, Milestone, had recorded on the Balance Sheet a $1.0 million Line of Credit from a stockholder, originally issued in June 2007. The full line was utilized at year end. Subsequent to March 31, 2008 the line of credit was increased by $300,000 to $1,300,000. All terms and conditions remained unchanged.

          The Company has incurred operating losses and negative cash flows from operating activities since its inception. The Company is actively pursuing the generation of positive cash flows from operating activities through increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses; however, the Company does not have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months. The Company anticipates the need for a higher level of marketing and sales efforts that at present it cannot fund. If the Company is unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that traditional capital can be raised on terms and conditions satisfactory to the Company. If additional capital is required and cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company’s operating results.

          The Company’s recurring losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the three months ended March 31, 2008, Milestone did not hold a portfolio of securities instruments for trading or speculative purposes.

Reference is made to Item 2 of Part I of this quarterly report. “Management Discussion and Analysis or Plan of Operation-Forward Looking Statements”.

Item 4. Controls and Procedures

The Company’s management, including the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of March 31, 2008 are effective to ensure that information required to be disclosed in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

Management’s Report on Internal Control over Financial Reporting

There have been no significant changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the Company’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

          In August of 2007 Milestone commenced a Declaratory Judgment Action against Milton Hodosh, DMD in the United States District Court for the District of New Jersey seeking a determination by that Court that neither its STA™ Injection System nor its CompuDent^® system infringed claims set forth in United States Patent No. 6159161 filed by Dr. Hodosh on July 8, 1998 and issued by the United States Patent Office on December 12, 2000. Milestone’s basic patents covering these systems were issued by the United States Patent Office in January 1993. Subsequent to the commencement of Milestone’s action for a Declaratory Judgment, Dr. Hodosh commenced a patent infringement suit in the United States District Court for the Southern District of New York alleging that he is the owner of all rights to a patent issued to him in 2000 that relates to a method and system for painlessly delivering oral anesthesia to dental patients by controlling the rate of flow or pressure of the anesthetic and that Milestone has infringed and is continuing to infringe his patent by manufacturing and selling its products, including the STA™ Injection System, the CompuDent^® Computer Controlled Anesthetic Delivery System and a product line of CompuMed^® anesthetic and fluid delivery products. Dr. Hodosh seeks a declaration that his patent is valid and enforceable and is being infringed upon by Milestone, an injunction from further infringement, unspecified damages but in no event less than a reasonable royalty, and that such damages be trebled due to the alleged willful nature of the infringement.

          On November 5, 2007, Milestone filed an Answer, Affirmative Defenses and Counterclaims against Dr. Hodosh. The answer denied the material allegations of the complaint and asserted thirteen affirmative defenses including that the products offered by Milestone involve apparatus and methods that are not infringing on Dr. Hodosh’s patent and that Dr. Hodosh’s patent is invalid and/or unenforceable. The Counterclaims seek, inter alia, a declaration of non-infringement and that Dr. Hodosh’s patent is invalid. Milestone has received opinions from patent counsel, not involved in the litigations, that neither the STA^™ system nor the Compudent^™ system infringe any of the claims of Dr. Hodosh’s patents. After the commencement of Dr. Hodosh’s action, Milestone withdrew its prior action so that the entire matter could be determined in one forum. Milestone believes that it has meritorious defenses to Dr. Hodosh’s claims and intends to vigorously defend the action and pursue counterclaims. The case is currently in the discovery phase.

ITEM 1A. RISK FACTORS

          The following factors may affect the growth and profitability of Milestone and should be considered by any prospective purchaser or current holder of Milestone’s securities:

We have no history of profitable operations. Continuing losses could exhaust our capital resources and force us to discontinue operations.

          For the months ended March 31, 2008 and 2007 our revenues were approximately $1.4 million and $2.3 million respectively. In addition, we have had losses for each year since the commencement of operations, including net losses of approximately $616,000 and $535,000 for 2008 and 2007, respectively. At March 31, 2008, we had an accumulated deficit of approximately $56.7 million. At March 31, 2008, the Company had cash and cash equivalents $237,715 and working capital of $1,551,088. Additionally, the Company secured a line of credit in the aggregate amount $1.0 million from a stockholder which line was fully borrowed at December 31, 2007, as discussed in Note B, item 10. Subsequent to March 31, 2008, the line of credit was increased by $300,000 to $1,300,000. All terms and conditions remained unchanged. The Company is actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses; however, the Company does not now have sufficient cash reserves to meet all of its anticipated obligations for the next 12 months. The Company anticipates a need for a higher level of marketing and sales efforts that at present it cannot fund. If the Company is unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that additional capital can be raised on the terms and conditions satisfactory to the Company if at all. If additional capital is required and it cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost savings measures, any of which might negatively affect the Company’s operating results.

          The Company’s recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.

          There are no other changes to our risk factors from those disclosed in our Annual Report on Form 10-KSB for the year ended December 31, 2007.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

          In the quarter ended March 31, 2008, Milestone issued total 331,542 shares valued at $504,679 as follows:

		Shares				$
Shares issued for Employee Compensation			9,314			$	15,832
Shares issued to Vendors for services			156,448				262,748
Shares issued for services			165,780				226,099
			331,542			$	504,679

          Additionally, in the quarter ending March 31, 2008, shares to be issued was increased by 83,333 shares of common stock (valued at $100,000) in settlement of deferred compensation with an officer of the Company.

          In the quarter ending March 31, 2007, Milestone issued a total of 15,001 shares valued at $22,300.

ITEM 3. DEFAULT UPON SENIOR SECURTIES

          NONE

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

          NONE

ITEM 5. OTHER INFORMATION

          NONE

ITEM 6. EXHIBITS

  The following exhibits are filed herewith:

	31.1		Chief Executive Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
	31.2		Chief Financial Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
	32.1		Chief Executive Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
	32.2		Chief Financial Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		MILESTONE SCIENTIFIC INC.
		/s/ Joe W. Martin   Joe W. Martin
		Chief Executive Officer
		/s/ Joseph D’Agostino   Joseph D’Agostino
		Chief Financial Officer

Date: May 15, 2008